Time Kills More Raises Than Metrics
Founders obsess over their numbers. The variable that actually determines outcomes is the one they track least.
Field notes, presume tests, and insights from the funding trenches.
Founders obsess over their numbers. The variable that actually determines outcomes is the one they track least.
Every rejection you receive is diagnostic data. Most founders throw it away. The ones who survive read it like an x-ray.
After 300+ diagnostics, the pattern is clear: founders raise for a company that exists only in their heads.
Investors reference-check founders through their network before, during, and after your pitch. Here is how to manage it.
You got the second meeting. The process was real. Here is where it falls apart.
The rejection phrases investors use and what they are really saying.
Most founders follow up wrong. Here is what moves investors from maybe to yes.
The reference calls that make or break your deal. And how to prepare for them.
Sometimes the best fundraising decision is to wait.
Investors aren't being malicious. They're just optimizing for information asymmetry.
Testing the assumption that repeat founders dominate Series A fundraising.
Founders optimize for the wrong room. The decision happens before you arrive and after you leave.
You built the better product. They raised the bigger round. Here's the strategic failure that explains almost every case.
A startup took bridge financing to 'extend runway for Series A.' Eighteen months later, they're still bridging.
The translation guide for soft passes. Learn to read between the lines and know when to move on.
Testing the assumption that non-technical solo founders can't raise Series A.
A folder-by-folder structure that answers investor questions before they ask them.
Your dashboard says you're winning. Your investors see something different. Here's why the gap exists.
A seed-stage company with $800K ARR tried to raise Series A. The market taught an expensive lesson.
A peek inside the partner meeting. The three questions that determine your fate.
Testing the assumption that you must secure a lead before approaching other investors.
Everything founders need to know about raising Series A in 2026: benchmarks, timelines, metrics, and the mistakes that kill deals.
A proven 4-email sequence for staying top of mind without being annoying.
The founders who need warm intros the most are the ones least likely to get them. Here's how to break the cycle.
A founder with $2.4M ARR and 140% NRR got passed over 23 times. The problem wasn't the numbers.
Testing the assumption that founder-led sales must end before Series A.
Real data from 47 Series A closes in Q4 2025 and Q1 2026. What actually got funded, and at what terms.
Pro-rata rights are back on the table. Here's what's actually changing.
VCs will ask for 50 metrics. Only 7 actually drive the investment decision. Here's what they are and how to present them.
A $1.8M ARR construction tech startup couldn't close. The unit economics told the story.
A realistic week-by-week breakdown of the Series A process, from first meeting to wire.
After 300+ diagnostics, these are the patterns that consistently derail Series A raises.
A proven format for keeping investors warm without wasting their time.